Shenzhen Hornetcorn Bio-technology CompanyLTD
CIK cell therapy(Shenzhen Hornetcorn Bio-technology Company, LTD)은 Non Small Cell Lung Cancer 표적 세포·유전자 치료로, Non Small Cell Lung Cancer 영역에서 개발·상용화 중입니다. 작용기전: target BL cells via the Fas-FasL axis rather than the NKG2D pathway. 전임상 단계입니다. ClinicalTrials.gov 기준 54건의 관련 임상이 등록되어 있습니다. 차별점: novel contribution is the explicit inclusion of both cellular (cytotoxic T-lymphocytes, CTLs) and humoral (antibody) immune r.
Non Small Cell Lung Cancer
Non Small Cell Lung Cancer
Active
CAR-T trials comprising 60 % of recent studies
retroviral therapy or intrinsic immune clearance, and logistic growth for CD4[Formula: see
novel contribution is the explicit inclusion of both cellular (cytotoxic T-lymphocytes, CTLs) and humoral (antibody) immune r
target BL cells via the Fas-FasL axis rather than the NKG2D pathway
T cell response as a feedback-controlled program, wherein the rates of activation
apoptosis was significantly and comparably increased by probiotics and CIK cells, and these effects were further significantly en
PD-1 expression
escape biomarker (PD-L1) among the groups (all p<0
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Shenzhen Hornetcorn Bio-technology CompanyLTD
CIK cell therapy(Shenzhen Hornetcorn Bio-technology Company, LTD)은 Non Small Cell Lung Cancer 표적 세포·유전자 치료로, Non Small Cell Lung Cancer 영역에서 개발·상용화 중입니다. 작용기전: target BL cells via the Fas-FasL axis rather than the NKG2D pathway. 전임상 단계입니다. ClinicalTrials.gov 기준 54건의 관련 임상이 등록되어 있습니다. 차별점: novel contribution is the explicit inclusion of both cellular (cytotoxic T-lymphocytes, CTLs) and humoral (antibody) immune r.
Non Small Cell Lung Cancer
Non Small Cell Lung Cancer
Active
CAR-T trials comprising 60 % of recent studies
retroviral therapy or intrinsic immune clearance, and logistic growth for CD4[Formula: see
novel contribution is the explicit inclusion of both cellular (cytotoxic T-lymphocytes, CTLs) and humoral (antibody) immune r
target BL cells via the Fas-FasL axis rather than the NKG2D pathway
T cell response as a feedback-controlled program, wherein the rates of activation
apoptosis was significantly and comparably increased by probiotics and CIK cells, and these effects were further significantly en
PD-1 expression
escape biomarker (PD-L1) among the groups (all p<0
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.